This study assessed the accuracy of bacterial and yeast identification using the VITEK MS, and the time to reporting of isolates before and after its implementation in routine clinical practice. Three hundred and sixty-two isolates of bacteria and yeast, consisting of a variety of clinical isolates and American Type Culture Collection strains, were tested. Results were compared with reference identifications from the VITEK 2 system and with 16S rRNA sequence analysis. The VITEK MS provided an acceptable identification to species level for 283 (78 %) isolates. Considering organisms for which genus-level identification is acceptable for routine clinical care, 315 isolates (87 %) had an acceptable identification. Six isolates (2 %) were identified incorrectly, five of which were Shigella species. Finally, the time for reporting the identifications was decreased significantly after implementation of the VITEK MS for a total mean reduction in time of 10.52 h (P,0.0001). Overall, accuracy of the VITEK MS was comparable or superior to that from the VITEK 2. The findings were also comparable to other studies examining the accuracy of the VITEK MS, although differences exist, depending on the diversity of species represented as well as on the versions of the databases used. The VITEK MS can be incorporated effectively into routine use in a clinical microbiology laboratory and future expansion of the database should provide improved accuracy for the identification of micro-organisms.
INTRODUCTION
Use of matrix-assisted laser desorption/ionization time-offlight (MALDI-TOF) MS in microbiology has been shown to be reliable and accurate (Benagli et al., 2011; van Veen et al., 2010; Bizzini et al., 2010 Bizzini et al., , 2011 Cherkaoui et al., 2010; Seng et al., 2009) , with numerous clinical laboratories incorporating the new method into routine practice throughout the world. It reduces cost per sample of consumables, reduces technologist time and improves turnaround time spent for final identification (Bizzini et al., 2010; Cherkaoui et al., 2010; Dhiman et al., 2011; Seng et al., 2009) . In the last few years, many papers have emerged describing the use of MALDI-TOF MS in all areas of microbiology, primarily in the identification of bacteria, mycobacteria, yeast and filamentous fungi, as well as in bacterial taxonomic and epidemiological studies (Murray, 2010) .
Two different systems are available commercially: the Microflex LT MALDI-TOF mass spectrometer with the Biotyper database (Microflex Bruker Daltonics) and the VITEK MS system with the SARAMIS database (bioMérieux), with many publications describing the use of the Bruker system, which has been reported to provide correct bacterial and yeast identification to species level from 73 to 92 % (Bizzini et al., 2010 (Bizzini et al., , 2011 Cherkaoui et al., 2010; Sogawa et al., 2012; van Veen et al., 2010) . The VITEK MS has shown similar capabilities and performance in identifying almost all bacteria and yeasts of medical importance (Benagli et al., 2011; Cherkaoui et al., 2010; Justesen et al., 2011; Veloo et al., 2011; Martiny et al., 2012; Rosenvinge et al., 2013) .
The objectives of this study were to assess the accuracy of bacterial and yeast identification as well as turnaround time to reporting of isolate identification using the VITEK MS in the clinical microbiology laboratory. Most current published studies have examined the accuracy of the Bruker MALDI-TOF instrument, while fewer studies have examined the accuracy of the VITEK MS, and of those that do, many focus on only individual groups of organisms, such as anaerobes or non-fermenters (Carbonnelle et al., 2012; Justesen et al., 2011; Marko et al., 2012; Veloo et al., 2011) . This study is also in contrast to some of the previously reported studies in that the performance of the VITEK MS was analysed without the use of protein extraction for the bacterial isolates.
Finally, previous comparisons of time to identification between MALDI-TOF MS and biochemical methods reflected essentially the difference of procedural times (Cherkaoui et al., 2010; Tan et al., 2012) . However, similar to the study by Tan et al. (2012) (who reported on the Bruker system), in this study the true turnaround time for reporting identifications from clinical specimens received in the laboratory was prospectively evaluated, as the VITEK MS was applied in routine clinical practice.
METHODS
A total of 362 isolates (comprising 147 unique species) were tested from a selection of 272 consecutive clinical bacterial and yeast isolates as well as 90 American Type Culture Collection (ATCC) strains used routinely in the laboratory. The clinical specimens were collected from hospitalized and ambulatory patients at the University of Chicago Medicine from June 2011 to October 2011. The clinical bacterial and yeast isolates originated from the following sources: blood (50), tissue and wounds (42), respiratory samples (77), urine (51), body fluids including cerebrospinal fluid (29) and miscellaneous (23).
Clinical isolates included the majority of genera commonly isolated in the clinical setting as well as rare organisms. The 90 ATCC collection strains were added to ensure an even broader range of pathogens. The clinical isolates were all identified in real-time, using traditional methods of identification, as part of routine patient care. This included culture using a variety of media types used routinely in the clinical microbiology laboratory: BBL trypticase soy agar with 5 % sheep blood (TSA II), chocolate II agar, buffered charcoal yeast extract agar, MacConkey agar, colistin-nalidixic acid agar, Brucella 5 % sheep blood agar with haemin and vitamin K1, and Sabouraud dextrose agar Emmons (SAB) (all from Becton Dickinson Microbiology Systems). Isolates were identified using traditional methods of identification, which included mainly biochemical kits such as the API NH (bioMérieux), BactiStaph and Streptex latex agglutination kits, and RapID NF+ (Remel) or the VITEK 2 system using the GP, GN and YST cards (bioMérieux). Shigella and Salmonella isolates were subtyped additionally using their respective BD Difco antisera. All isolates were then stored frozen in a 1 : 1 mixture of Mueller-Hinton broth and inactivated horse serum (or skimmed milk for the anaerobes) prior to analysis by the VITEK MS. After thawing, fastidious organisms were subcultured twice to chocolate II agar, anaerobes to Brucella 5 % sheep blood agar with haemin and vitamin K1, yeasts to SAB, and all other isolates to TSA II. All were incubated overnight at 36±1 uC; the anaerobes were incubated for 48 h.
VITEK MS MALDI-TOF MS analyses. VITEK MS MALDI-TOF identification was performed with the VITEK MS RUO, also known as the Axima Assurance mass spectrometer, with the SARAMIS database (bioMérieux). VITEK MS analyses were performed according to the manufacturer's instructions (Global Customer Service, 2010) and as described by Martiny et al. (2012) . Isolates were tested simultaneously, in duplicate, for a total of 860 tests in 23 runs.
Briefly, FlexiMass target slides were inoculated by picking up a freshly grown overnight colony with a 0.001 ml calibrated disposable plastic loop and then adding 1 ml matrix solution, a-cyano-4-hydroxycinnamic acid. Standards performed on each slide were two spots of Escherichia coli ATCC 8739. Extraction with 25 % formic acid was performed on the plate, only for yeast isolates, following the procedure outlined by the manufacturer (Global Customer Service, 2010) . Once dry, the target plate was loaded into the Axima Assurance mass spectrometer (bioMérieux), where mass spectra were generated in a linear positive mode with a laser frequency of 50 Hz and with a molecular mass range of 2-20 kDa, using software version 3.5.1.3. Mass spectra were compared with the SARAMIS (Spectral Archive and Microbial Identification System) database version 4.09 (originally developed by AnagnosTec, which contains ReferenceSpectra for 1161 bacteria, and 263 mycota and yeast, and SuperSpectra for 552 bacteria, and 139 mycota and yeast (Global Customer Service, 2010) . The SuperSpectra are 'created on the basis of multiple isolates of a taxon (usually a species)' and are used 'for the fully automated firstline identification of microbial samples' (Global Customer Service, 2010). ReferenceSpectra, which can be used for lower criteria of acceptance, were not used in this study.
The spectra are therefore matched against the database and matches that yielded identification results are listed with their respective confidence percentage.
All of the correct identifications to species level with a score ¢80 % were considered as acceptable identifications. Correct genus-only identifications with a score ¢80 % were considered acceptable only for those identifications the laboratory reports routinely to genus level only.
Classification. Results obtained were classified into the following categories: 'correct identification of species', 'correct identification to genus only', 'acceptable identification to genus only', 'misidentification' and 'no identification'. 'Not identified' organisms included organisms that could not be identified, as well as organisms that were identified but with an unacceptable score or with a comment suggesting low genus discrimination, even if the identification was correct. Further, 'correct identification of genus only' is not always an acceptable identification for reporting patient results. 'Total acceptable (reportable) identification' therefore includes only the categories 'correct identification of species' and 'acceptable identification to genus only'.
Discrepancies. Discrepancies were defined as different genus-or species-level identification obtained from the VITEK MS compared with the traditional methods. The first response to a discrepancy (or non-identification) was to subculture the isolates, and repeat both VITEK MS and identification using traditional methods. If further resolution of an identification was required, the isolates were sent to a reference laboratory for 16S rRNA gene sequencing using universal 16S rRNA-specific primers. Identifications were considered acceptable if at least one of the VITEK MS test results was correct and none was incorrect.
Timeliness estimates. The isolates used to study turnaround time were not the same as those used to assess method accuracy. In realtime, the turnaround time of 492 consecutive clinical bacterial and yeast isolates was assessed using traditional methods of identification prior to implementation of the VITEK MS. Later, in real-time, the turnaround time of 466 consecutive clinical bacterial and yeast isolates was assessed prospectively after implementation of the VITEK MS in routine clinical practice (referred to as the MALDI-TOF ID protocol). Turnaround time was defined as the difference between the time the specimen was received in the microbiology laboratory and the time the result was reported in the patient's electronic medical record. The MALDI-TOF ID protocol included two supplementary tests maintained in clinical use after implementation of the VITEK MS because of ease of workflow: the BactiStaph and Streptex latex agglutination kits (Remel). The time used in the turnaround time evaluation of the MALDI-TOF ID protocol included the time required when multiple attempts at identification were performed on an isolate, and any resolution of discrepancies, to ensure that the evaluation of timeliness remained true to the way in which the VITEK MS was used in actual routine clinical practice. Timeliness estimates were not limited to any particular days of the week, and included weekends and weekdays. Evaluation of turnaround time was performed with the routine rotation of technologists in the laboratory, thus balancing any differences in technologist-specific variation in time to evaluate the plates of a culture.
Statistical methods. Unpaired t-test and Mann-Whitney analyses were performed to compare the time to reporting of the isolate identification before and after implementation of the VITEK MS.
RESULTS
The individual isolates tested by the VITEK MS for the accuracy portion of the study are listed in Table S1 (available in JMM Online). A summary of the identifications by organism group is given in Table 1 . Of the 362 total bacteria and yeast tested, 283 (78 %) had an acceptable identification to species level. For some organisms, reporting the genus only is acceptable for routine clinical care, as indicated in Table S1 , when no species is designated. Therefore, when including acceptable genusonly identifications, a total of 315 isolates tested (87 %) had an acceptable identification.
Twenty-nine isolates (8 %) were not identified with a confidence score of ¢80 %, even after repeat analysis, and were therefore considered 'No ID'. Nine of these (Candida parapsilosis, Candida lusitaniae, Candida sporogenes, Aggregatibacter aphrophilus, Citrobacter freundii, Enterobacter cloacae, a saprophytic Neisseria species and two isolates of Corynebacterium jeikeium) were identified correctly at a confidence level between 75 and 80 % to the species or genus level, but this did not meet the cut-off established for an acceptable identification. Four of the unidentified isolates were not included in the SARAMIS database (Table S1 ). Some of the remaining isolates were identified correctly by the ReferenceSpectra with a lower confidence score (¡70 %) and were also considered as 'No ID'. Isolates not identified with a score of ¢80 % are listed individually in Table S1 .
Sixteen isolates were sent to a reference laboratory for 16S rRNA gene sequencing (Table 2 ). Of the 13 isolates for which the VITEK MS provided an identification, sequencing confirmed the identification given by the VITEK MS for all but one of the discrepant isolates. The VITEK MS misidentified one isolate of Bacillus cereus/thuringiensis as Bacillus weihenstephanensis.
Misidentification occurred with a total of six isolates (2 %), one B. cereus/thuringiensis and all five Shigella species (Shigella boydii, Shigella dysenteriae, two isolates of Shigella Correct species identification
Gram-negative bacilli 149 25 (17) 13 (9) 109 (73) 5 (3) 10 (7) 122 (82) Non-fermenters 43 (29*)
14 (33) 11 (26) 28 (65) 0 (0) 1 (2) 39 (91) Enterobacteriaceae 65 (44*)
6 (9) 1 (2) 49 (75) 5 (8) 5 (8) 50 (77) Other 41 (28*)
5 (12) 1 (2) 32 (78) 0 (0) 4 (10) 33 (80) Gram-positive cocci 84 7 (8) 7 (8) 73 (87) 0 (0) 4 (5) 80 (95) Gram-positive bacilli 20 1 (5) 1 (5) 12 (60) 1 (5) 6 (30)
(65)
Anaerobes 27 7 (26) 7 (26) 15 (56) 0 (0) 5 (19)
(81)
Yeast 82 4 (5) 4 (5) 74 (90) 0 (0) 4 (5) 78 (95) Total (%) 362 44 (12) 32 (9) 283 (78) 6 (2)D 29 (8) 315 (87) *Per cent of the total Gram-negative bacilli. DFive Shigella isolates and one Bacillus cereus/thuringiensis.
Comprehensive evaluation of the VITEK MS
flexneri and Shigella sonnei). All Shigella species were misidentified as E. coli. The Shigella isolates were not sent for resolution by molecular methods, as they were all ATCC strains that had been validated repeatedly in the laboratory in their use as quality control organisms. Resolution of this discrepancy was instead performed by the VITEK 2 system using the GN card (bioMérieux), as well as by serological subtyping using the BD Difco Shigella antisera.
Finally, there were no discrepancies in organism identification between the duplicate spots on the MALDI slides. For six isolates, one spot gave an acceptable identification, whilst the other did not yield a spectrum. For another 21 isolates, one spot gave an acceptable identification, whilst the other could not identify the organism to genus level with the appropriate confidence of 80 %, but the identification provided was not incorrect.
Turnaround time analysis is illustrated in Fig. 1 . Mean turnaround time for final identification of all organisms was 60.50 h before and 49.98 h after implementation of the VITEK MS. There was a statistically significant decrease in overall turnaround time after implementation of the VITEK MS (P,0.0001), with a total reduction in time of 10.52 h (17.39 %). For the Gram-positive bacilli, Gramnegative cocci and anaerobes, the total number analysed for turnaround time was small, and the difference was not significant. For all other organism groups (Grampositive cocci, P50.026; Gram-negative bacilli, P,0.0001; Enterobacteriaceae, P50.0048; yeast, P50.0274), the difference was statistically significant.
DISCUSSION
The VITEK MS performance as related to accuracy has been well-described (Carbonnelle et al., 2012; Justesen et al., 2011; Marko et al., 2012; Martiny et al., 2012) . However, the present study is unique in that it provides a comprehensive evaluation of the system, evaluating not only accuracy, for an extensive variety of bacteria and yeast, but also turnaround time, as the instrument is applied in routine clinical practice.
Overall, accuracy of the VITEK MS was comparable to that of traditional methods of identification, and to results of other studies that have examined the accuracy of the Bruker MALDI-TOF and VITEK MS instruments (Bader et al., 2011; Justesen et al., 2011; Martiny et al., 2012; Veloo et al., 2011) . There was an overall correct identification to species level for 78 % of isolates and an overall acceptable identification of 87 %. These results are comparable to those reported by Martiny et al. (2012) who obtained an 83.8 % overall acceptable identification to species level, using an 80 % cut-off. Carbonnelle et al. (2012) reported an overall acceptable identification to species level of 93.4 % for biochemically easy-to-identify routine clinical isolates, but only 65.9 % for collection strains, highlighting the fact that the selection of organisms can impact dramatically the perceived accuracy of identifications by the VITEK MS.
In this study, the VITEK MS performed best for the Grampositive cocci and for yeast, with a total acceptable identification of 95 % for each group. The VITEK MS showed a less reliable performance for the anaerobes, with The six isolates that were incorrect by traditional methods of identification are given in bold. *The VITEK MS misidentified one isolate of B. cereus as B. weihenstephanensis. Other identifications given by the VITEK MS were correct. DTwo clinical isolates could not be identified by traditional means in the laboratory and were also not identified by the VITEK MS; their 16S rRNA identification was therefore considered the correct identification.
only a 56 % identification to species level. This could be, in part, due to the small number of anaerobes tested in the present study (only 27 isolates), although 18 different species were represented. However, Justesen et al. (2011) reported a 49 % identification to species level, testing 290 anaerobic isolates, and Martiny et al. (2012) reported only a 9.6 % correct identification to species level, testing 73 anaerobic isolates. On the contrary, Carbonnelle et al. (2012) obtained good results using a limited selection of anaerobes, with accurate identifications of 94.4 % to genus level and 83.3 % to species level. Interestingly, this group only tested 18 anaerobic isolates, of which 15 (83 %) were of the Bacteroides genus, which have been reported to be identified less accurately by the SARAMIS than the Bruker Biotyper database (Knoester et al., 2012; Veloo et al., 2011) . Jamal et al. (2013) reported 100 % correct identification to species level, testing 274 anaerobic isolates, using an even more stringent (90 %) confidence score cut-off. Finally, Barreau et al., (2013) analysed 1325 anaerobic isolates using the Bruker instrument, and reported 92.5 % sensitivity of identification to the species level and 6.5 % to the genus level. Therefore, the reasons for the discrepancies between the various studies remain uncertain, although differences in database versions, organism repertoire and variations in sample preparation methods likely contribute.
These vast differences in findings are troublesome, particularly because the identification of anaerobes with traditional methods can be laborious and difficult, making their accurate and timely identification by the VITEK MS of particular importance. MS is therefore a promising tool in the identification of anaerobic bacteria, but requires further optimization and standardization.
For the Enterobacteriaceae, 75 % of isolates identified correctly to species level. Using an 80 % cut-off for the SARAMIS database, Martiny et al. (2012) obtained only a 35 % acceptable species identification for the enteropathogenic Gram-negative bacilli. This could be explained, in part, by the fact that this group tested enteropathogens and not strict Enterobacteriaceae.
The Gram-positive bacilli identified with the lowest accuracy, 60 % to species level. Carbonnelle et al. (2012) , however, reported an acceptable identification of only 10.5 % to species level for the Gram-positive bacilli. A small number of Gram-positive bacilli were tested in the present study, but the reasons for the discrepancies among studies remain uncertain.
As expected, all Shigella species were misidentified as E. coli due to the close relatedness of the organisms, requiring an alternative identification algorithm in the routine clinical setting. The only other misidentified isolate was a B. cereus that the VITEK MS identified as B. weihenstephanensis, a species that should be distinguished from B. cereus, both phenotypically and genetically (Markland et al., 2013) .
For a variety of reasons, the results between published reports are sometimes conflicting. These reasons may include the use of earlier versions of the instrumentation and database, a different repertoire of organisms tested, different criteria for an acceptable cut-off score, and different definitions for what constitutes an acceptable identification (Carbonnelle et al., 2012; Cherkaoui et al., 2010; Knoester et al., 2012; Martiny et al., 2012) . Further, some of the European studies describe accuracy using the VITEK MS IVD (bioMérieux, France), which should not be confused with the VITEK MS SARAMIS, now also known as the VITEK MS RUO, the system examined in this study.
Finally, turnaround time for identification of an isolate improved significantly with implementation of the VITEK MS. Mean turnaround time for final identification of all organisms was 60.50 h before and 49.98 h after implementation of the VITEK MS, giving a total reduction of 10.52 h after implementation of the VITEK MS. Additionally, overall work flow became more efficient with the use of one primary method of identification as opposed to many methods (numerous biochemical tests, VITEK 2, rapid identification strips), along with the lack of a need for subculture. The inventory and quality control materials needed for identifications also decreased with implementation of the VITEK MS. The VITEK MS can identify more organisms using less complex algorithms -a fact that has streamlined and standardized processes in the laboratory. Tan et al. (2012) , who studied the Bruker model, reported that, on average, the MALDI-TOF protocol provided an identification of bacterial isolates 1.45 days earlier than traditional methods of identification. Their analyses, however, included only the isolates that had their MALDI-TOF protocol finalized on weekdays and they did not incorporate the use of genus-level identification in their study. Further, their study did not include a comparison of the MALDI-TOF protocol with rapid presumptive-identification methods, such as those available for Staphylococcus aureus and E. coli -methods that can be performed directly at the bench and that may be faster than the MALDI-TOF protocol.
No information was eliminated in the present analysis of turnaround time which was measured using objective data from the time the specimen was received in the laboratory to the time the result was reported in the patient's electronic medical record. Repeat runs and the use of rapid traditional testing methods as performed in parallel, when appropriate, were therefore all taken into account for the time analysis according to real work flow in the laboratory, which processes specimens 24 h per day, 7 days per week. In the laboratory, culture plates are read during the first 8 h daytime shift and MALDI-TOF slides are prepared three times per day, on average, with 50-60 isolates identified by the VITEK MS per day. In actual practice, turnaround time will be affected by size of the laboratory, number and type of clinical specimens received, access and frequency of alternative methods of identification, and staffing/work flow issues.
A limitation of this study is that a parallel comparison was not done in the assessment of turnaround time. Specifically, the same specimens were not tested by both the old and new methods in parallel for turnaround time analysis. However, the analysis did include a similar number of each type of organism before and after implementation of the VITEK MS, such that the composition of the species represented is not identical, but similar.
It is expected that, with future expansion of the database, the VITEK MS will be an even more cost-effective, accurate method for identification of bacterial and yeast isolates that can be effectively incorporated into routine use in a clinical microbiology laboratory. Patients can benefit from earlier treatment and possibly shorter hospital stays. Cost savings can result from more prompt and directed care as well as from sending fewer isolates to reference laboratories for identification.
